PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
34.57%
Cash & equivalents growing 34.57% while AVXL's declined -9.60%. Peter Lynch would see this as a sign of superior liquidity management.
68.63%
Higher Short-Term Investments Growth compared to AVXL's zero value, indicating better performance.
34.59%
Below half of AVXL's -9.60%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.58%
Below half of AVXL's -9.73%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-15.03%
1.25-1.5x AVXL's -12.46%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-11.19%
0.75-0.9x AVXL's -12.46%. Bill Ackman questions if the competitor invests more robustly in future growth.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Below half of AVXL's -9.73%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-18.99%
Less than half of AVXL's 8.86%. David Dodd sees a more disciplined AP approach or lower volume.
-51.38%
Above 1.5x AVXL's -8.04%. Michael Burry sees a major discrepancy in short-term leverage. Check coverage and liquidity carefully.
No Data
No Data available this quarter, please select a different quarter.
-91.88%
≥ 1.5x AVXL's -8.86%. David Dodd sees stronger subscription/prepayment demand.
-10.37%
Less than half of AVXL's -100.00%. David Dodd sees fewer expansions in other current obligations.
-15.50%
Less than half of AVXL's 7.77%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-15.50%
Less than half of AVXL's -74.73%. David Dodd sees far fewer liability expansions relative to competitor.
13.39%
50-75% of AVXL's 18.37%. Bruce Berkowitz notes minimal new equity relative to competitor.
-7.92%
≥ 1.5x AVXL's -3.23%. David Dodd sees higher yoy retained profits than competitor.
-32.48%
1.25-1.5x AVXL's -24.48%. Martin Whitman is wary of bigger swings in AOCI.
No Data
No Data available this quarter, please select a different quarter.
41.56%
Below half AVXL's 893.88%. Michael Burry sees potential underperformance in building shareholder capital.
31.29%
Below half AVXL's -9.73%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
68.63%
Higher Total Investments Growth compared to AVXL's zero value, indicating better performance.
-51.38%
50-75% of AVXL's -95.74%. Bruce Berkowitz sees relatively smaller yoy debt additions.
-35.43%
Less than half of AVXL's -253.17%. David Dodd sees better deleveraging or stronger cash buildup than competitor.